XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
MedSurg$948 $576$1,808 $1,350
Rhythm and Neuro866 5251,617 1,228
Cardiovascular1,263 8342,392 1,860
Total net sales of reportable segments3,077 1,9355,816 4,437
All other (Specialty Pharmaceuticals)(1)
— 6813 109
Net sales$3,077 $2,003$5,829 $4,546
MedSurg$363 $173$695 $432
Rhythm and Neuro168 32316 131
Cardiovascular418 186756 385
Total operating income of reportable segments949 3911,767 947
All other (Specialty Pharmaceuticals)(1)
— 494 75
Unallocated amounts:
Corporate expenses, including hedging activities(176)(189)(329)(222)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and EU MDR implementation costs(331)(125)(445)(327)
Amortization expense(180)(197)(365)(398)
Operating income (loss)262 (71)632 75
Other expense, net(113)(110)(157)(234)
Income (loss) before income taxes$149 $(181)$474 $(159)
(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes for the first six months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.
Operating income margin of reportable segmentsThree Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
MedSurg38.3 %30.1 %38.5 %32.0 %
Rhythm and Neuro19.3 %6.1 %19.5 %10.7 %
Cardiovascular33.1 %22.3 %31.6 %20.7 %